報價延遲最少15分鐘:2026/06/08 10:56 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.745 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.53/-0.54
|
|
企業價值
372.32M
|
| 資產負債 |
|
每股賬面淨值
-4.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
893.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |
